Literature DB >> 2860883

Antihypertensive therapy and lipids. Evidence, mechanisms, and implications.

M H Weinberger.   

Abstract

Elevations in the levels of total serum cholesterol, triglycerides, and low-density lipoproteins increase the risk of coronary artery disease and atherogenesis. High-density lipoproteins (HDLs) are beneficial in removing lipid from tissues. High-risk men adhering to a diet and/or receiving cholestyramine to lower their elevated lipid levels had lowering of cardiac mortality. Hypertension is also a major risk factor for cardiovascular disease and for accelerated atherosclerosis. The benefit of blood pressure reduction may not be consistent in decreasing cardiovascular morbidity and mortality among all mildly hypertensive persons. Many antihypertensive agents may raise undesirable lipid fractions and/or lower HDL levels, enhancing the risk of cardiovascular disease, while others have few negative effects. Thus, the antihypertensive agent chosen may modify lipid levels and cardiovascular risk in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2860883

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  24 in total

1.  Low and conventional dose cyclopenthiazide on glucose and lipid metabolism in mild hypertension.

Authors:  G E McVeigh; E B Dulie; A Ravenscroft; D B Galloway; G D Johnston
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 2.  Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension.

Authors:  M G Myers; S G Carruthers; F H Leenen; R B Haynes
Journal:  CMAJ       Date:  1989-05-15       Impact factor: 8.262

Review 3.  Value of non-drug treatment and drug treatment in hypertension.

Authors:  L J Beilin
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Cost of antihypertensive treatment: a point of view from India.

Authors:  H K Bali; I S Anand
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

5.  Antihypertensive therapy, serum lipids, coronary heart disease and hypertension--balancing the risks and benefits of treatment.

Authors:  M C Houston
Journal:  West J Med       Date:  1986-08

6.  Billing numbers fight to continue despite court setback.

Authors:  G Zilm
Journal:  CMAJ       Date:  1987-03-01       Impact factor: 8.262

7.  Serum lipids and lipoproteins in ischaemic heart disease following withdrawal of long-term metoprolol treatment.

Authors:  G Olsson; S Rössner; N Rehnqvist
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.

Authors:  T L Foxall; G T Shwaery; A F Stucchi; R J Nicolosi; S S Wong
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

9.  A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.

Authors:  R Harper; C N Ennis; A P Heaney; B Sheridan; M Gormley; A B Atkinson; G D Johnston; P M Bell
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

Review 10.  Choosing the optimum therapy for older hypertensive patients.

Authors:  W H Birkenhäger
Journal:  Drugs Aging       Date:  1991-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.